Drug discovery for HIV/AIDS has resulted in many life-saving therapies, making a great impact on modern medicine. Even though new therapies are available many drugs are highly susceptible to resistance development, have poor bioavailability, and cause several side effects. Therefore, there is an urgent need for the development of new types of inhibitory compounds, with better resistance profiles, better bioavailability, higher affinity, and lower toxicity. We are synthesizing novel boronates that were designed as compounds with potential dual-mode, both competitive and associative, of HIV-1 protease inhibitory action. A library of straight chain and cyclic boronates are being synthesized with the hope that those compounds will demonstrate a greater inhibitory activity than their non-boronated analogs and currently used drugs.

Toward the synthesis of novel boronates as potential HIV-1 protease inhibitors

247th National Meeting (2014)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.